Comment on ‘an Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients’

Peter Selby*1 and Johnathan Joffe2

1Institute of Cancer and Pathology, Cancer Genetics Building, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK and 2Huddersfield Royal Infirmary, Department of Oncology, Lindley, Huddersfield HD3 3EA, UK

Sir,

We write to draw attention to the recently published strategy of the Association of Cancer Physicians (ACP; Baird et al., 2016). This ACP strategy reflects a significant evolution of medical oncology planning and practice in the United Kingdom. Previous strategies necessarily focused upon the development of medical oncology as a research-based discipline whose main contribution to cancer care was the development and delivery of systemic anti-cancer therapies (SACT). In the last three decades, a consequence of relatively late diagnosis compared with comparable countries (Forbes et al., 2013; Jensen et al., 2015). With the need to develop and deliver increasing SACT, which results from new scientific understanding of cancer and the epidemiological pressures of the ageing population, our discipline will continue to be one of the most rapidly growing of all medical specialties.

The strategy focuses on improving patient outcomes by a wide range of interventions and identifying the ways in which medical oncologists can contribute. It was ‘co-produced’ with cancer patients and is evidence-based with detailed supporting chapters written by ACP members and external advisors (Baird et al., 2016). Many of the recommendations of the Independent Cancer Taskforce in the UK (Independent Cancer Taskforce, 2015; ICTUK) are endorsed and integrated into our strategy. By working closely with other healthcare professionals, researchers, health service managers and, in particular, with patients, in implementing the recommendations of the Taskforce, we look forward to making a crucial and increasing contribution to improving cancer outcomes in the coming decades.

Having contributed substantially to the improvements in cancer outcomes over the past 25 years, we are greatly encouraged that over 50% of UK cancer patients now survive their disease for 10 years or more. You are at a time not only of unprecedented acceleration of knowledge with regards to all aspects of cancer, but also of rapid change in terms of patient management and new therapies. To deliver better outcomes for patients, we must overcome challenges over the next decade, such as increasing demand for cancer services, and financial constraint in the NHS. We are committed in working with our patients and colleagues to increasing demand for cancer services and financial constraint in the next 20 years.

To contribute to this vision, over the next 3–5 years the ACP will work to achieve three broad goals:

- A substantial contribution to the overall development of NHS services. By developing cancer services to cope effectively with pressures currently impacting on other parts of the NHS. We particularly identify the demand for acute oncology and the care of older cancer patients as areas in which most medical oncologists will increasingly engage.
- A substantial contribution to the development of innovative approaches to cancer care, by close collaboration with primary care and other health professionals, developing better access to high-quality diagnosis, prevention and treatment. We will exploit modern health informatics, and better support the rapidly growing number of cancer survivors. We will develop and promote the rapid adoption of evidence-based innovations arising from biomedical sciences creating a more precise approach to oncology, providing patients with higher probabilities of treatment success and lower probabilities of toxicity.

We will share and converge our goals and commitments with those of the ICTUK (Independent Cancer Taskforce, 2015) and with the other clinical and non-clinical bodies engaged in improving outcomes for cancer patients. We will work with the Royal College of Physicians (www.rcplondon.ac.uk) and our colleagues in Clinical Oncology (Royal College of Radiologists—RCR) converging our strategies and workforce plans (www.rcr.ac.uk) (Clinical oncology—the future shape of the specialty. Royal College of Radiologists (2014); Clinical oncology workforce: the case for expansion. Royal College of Radiologists (2014)). We have shared our strategy with the RCR early on and have agreed joint working where appropriate. We will collaborate and consult with cancer charities, including those that focus on individual tumour types, and with Macmillan Cancer Support (www.macmillan.org.uk) and Cancer Research UK (www.cancerresearchuk.org).

The authors declare no conflict of interest.

REFERENCES

Allemann C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, Ogubiyi OJ, Rachet B, Soeborg MJ, You H, Matsuda T, Bielka-Lastota M, Storm H, Tucker TC, Coleman MP. CONCORD Working Group (2015) Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972): 977–1010.

de Azambuja E, Ameye L, Paesmans M, Zielinski CC, Piccart-Gebhart M, Preusser M (2014) An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients. Eancermedicalsicle 10: 608.

Forbes IJ, Simon AE, Warburton F, Boniface D, Brain KE, Dassai A, Donnelly C, Haynes K, Hvidberg L, Lagerlund M, Lockwood G, Tishelman C, Vedsted P, Vignostad MN, Ramirez AJ, Wardle J, International Cancer Benchmarking Partnership Module 2 Working Group (2013) Differences in cancer awareness

LETTER TO THE EDITOR

www.bjcancer.com | DOI:10.1038/bjc.2016.168
and beliefs between Australia, Canada, Denmark, Norway, Sweden and the UK (the International Cancer Benchmarking Partnership): do they contribute to differences in cancer survival? *Br J Cancer* **108**: 292–300.

Independent Cancer Taskforce (2015) ‘Achieving World-Class Cancer Outcomes. A Strategy for England 2015-2020’. Independent Cancer Taskforce, 2015 Available at www.cancerresearchuk.org/sites/default/files/achieving_world-class_cancer_outcomes_-_a_strategy_for_england_2015-2020.pdf (accessed 26 May 2016).

Jensen H, Tørring ML, Olesen F, Overgaard J, Fenger-Gron M, Vedsted P (2015) Diagnostic intervals before and after implementation of cancer patient pathways – a GP survey and registry based comparison of three cohorts of cancer patients. *BMC Cancer* **15**: 308.

This work is published under the BJC’s standard license to publish agreement. After 12 months the license terms will change to a Creative Commons AttributionNonCommercial-Share Alike 4.0 Unported License.

*Correspondence: Professor P Selby; E-mail: p.j.selby@leeds.ac.uk
Published online 21 July 2016
© 2016 Cancer Research UK. All rights reserved 0007 – 0920/16